OTCMKTS:PBIO

Pressure BioSciences - PBIO Stock Forecast, Price & News

$1.35

+0.03 (+2.27%)

(As of 09/26/2022 12:00 AM ET)

Add

Compare

Today's Range: $1.27
▼
$1.40
50-Day Range: $1.32
▼
$1.85
52-Week Range: $1.27
▼
$2.74

Volume: 7,083 shs
Average Volume: 15,969 shs
Market Capitalization: $13.34 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Pressure BioSciences (OTCMKTS:PBIO) Stock

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.

Receive PBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pressure BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PBIO Stock News Headlines

September 13, 2022 | finance.yahoo.com

Pressure BioSciences to Expand on Pivotal Change in Business Strategy with Presentation at H. C. Wainwright Annual Global Investment Conference on September 13th

August 25, 2022 | msn.com

Novartis To Spinoff Sandoz Business To Create #1 European Generics Company

August 24, 2022 | finance.yahoo.com

Pressure BioSciences Secures Pivotal Cosmeceuticals Partnership for UST Platform With Dr. Denese SkinScience, 20-Year Leader With Over $0.5 Billion in QVC Sales

August 20, 2022 | marketwatch.com

InvestorNewsBreaks - Pressure BioSciences Inc. (PBIO) Enters Strategic Agreement with Canopy CBD Farms

August 19, 2022 | seekingalpha.com

Pressure Biosciences announces contract for October launch of hemp-derived CBD product

August 18, 2022 | finanznachrichten.de

Pressure BioSciences Inc.: Pressure BioSciences, Inc. to Discuss Second Quarter 2022 Financial Results and Provide Business Update

August 18, 2022 | finance.yahoo.com

Pressure BioSciences Announces Contract for October 2022 Launch of Breakthrough Hemp-Derived CBD Product, Estimating $2 Million Incremental 2023 Revenue

August 16, 2022 | finance.yahoo.com

Pressure BioSciences, Inc. to Discuss Second Quarter 2022 Financial Results and Provide Business Update

August 5, 2022 | finance.yahoo.com

Pressure BioSciences Doubles Growth Projections for UST Nanoemulsion Contracts Following Clear Confirmation of Unmet Needs in Exploding Cannabis Drinks Sector

July 21, 2022 | finance.yahoo.com

Pressure BioSciences Announces Second Contract for Toll Manufacturing of a CBD Nanoemulsion Product Using Its Proprietary Ultra Shear Technology Platform

July 6, 2022 | finance.yahoo.com

Pressure BioSciences to Expand on Upcoming Release of CBD Nanoemulsion Oral Spray at July 6th Emerging Growth Conference - Annual Revenue to PBI Expected to Exceed $1M

July 2, 2022 | morningstar.com

Pressure BioSciences to Participate in FORCE Family Office June 30th Webinar: Revolutionizing the Development of Plant-Based Food Products | Morningstar

June 30, 2022 | finance.yahoo.com

Pressure BioSciences to Participate in FORCE Family Office June 30th Webinar: Revolutionizing the Development of Plant-Based Food Products

June 14, 2022 | finance.yahoo.com

Pressure BioSciences' Ultra Shear Technology Positioned for Critical Enabling Role in Global $41 Billion (2027) Plant Protein Beverage Market

June 1, 2022 | finance.yahoo.com

Pressure BioSciences Discusses Launch of Early Access Program for Ultra Shear Technology for the Processing of Nanoemulsions with The Stock Day Podcast

May 24, 2022 | finanznachrichten.de

Pressure BioSciences Inc.: Emerging Technology Insider Releases New TechTalks Video Interview with Pressure BioSciences' CEO Richard T. Schumacher

May 24, 2022 | finance.yahoo.com

Emerging Technology Insider Releases New TechTalks Video Interview with Pressure BioSciences' CEO Richard T. Schumacher

May 21, 2022 | seekingalpha.com

Pressure BioSciences GAAP EPS of -$0.48, revenue of $0.48M

May 19, 2022 | finanznachrichten.de

Pressure BioSciences Inc.: Pressure BioSciences, Inc. Reports Q1 2022 Financial Results

May 6, 2022 | finanznachrichten.de

Pressure BioSciences Inc.: Pressure BioSciences Announces First Nanoemulsions Manufacturing Agreement Under Recently Released UST Early Access Program

May 4, 2022 | finance.yahoo.com

Pressure BioSciences Announces First Nanoemulsions Manufacturing Agreement Under Recently Released UST Early Access Program

May 3, 2022 | finance.yahoo.com

Pressure BioSciences to Present at the Planet MicroCap Showcase 2022 on May 4, 2022

April 27, 2022 | finanznachrichten.de

Pressure BioSciences Inc.: Pressure BioSciences Announces Early Access Program for UST Nanoemulsion Processing

April 27, 2022 | finance.yahoo.com

Pressure BioSciences Announces Early Access Program for UST Nanoemulsion Processing

April 20, 2022 | finance.yahoo.com

Pressure BioSciences, Inc. Discusses Commercialization of Their Revolutionary UST Platform and Their Planned 2022 Uplisting with The Stock Day Podcast

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pressure BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PBIO Company Calendar

Last Earnings: 11/17/2020
Today: 9/26/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Analytical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:PBIO
CUSIP: N/A
CIK: 830656
Web: www.pressurebiosciences.com
Phone: 508-230-1828
Fax: 508-230-1829
Employees: 12
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.02)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,150,000.00
Net Margins: -882.77%
Pretax Margin: -882.72%
Return on Equity: N/A
Return on Assets: -535.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.07
Quick Ratio: 0.02

Sales & Book Value

Annual Sales: $2 million
Price / Sales: 6.67
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.63) per share
Price / Book: -0.51

Miscellaneous

Outstanding Shares: 9,880,000
Free Float: 8,591,000
Market Cap: $13.34 million
Optionable: Not Optionable
Beta: 0.67

Key Executives

Mr. Richard T. Schumacher (Age 72)
Founder, Pres, CEO, Treasurer, Interim CFO, Clerk & Director
Comp: $355.18k

Dr. Alexander V. Lazarev Ph.D. (Age 57)
Chief Science Officer
Comp: $202.34k

Dr. Edmund Y. Ting Ph.D. (Age 67)
Sc.D. Ph.D., Sr. VP of Engineering
Comp: $256.92k

John B. Hollister
Director of Sales & Marketing

Key Competitors

View All Competitors

PBIO Stock - Frequently Asked Questions

How have PBIO shares performed in 2022?: Pressure BioSciences' stock was trading at $2.31 on January 1st, 2022. Since then, PBIO shares have decreased by 41.6% and is now trading at $1.35.
View the best growth stocks for 2022 here.
Are investors shorting Pressure BioSciences?: Pressure BioSciences saw a increase in short interest during the month of August. As of August 15th, there was short interest totaling 9,900 shares, an increase of 19.3% from the July 31st total of 8,300 shares. Based on an average daily trading volume, of 30,400 shares, the short-interest ratio is currently 0.3 days.
View Pressure BioSciences' Short Interest.
How were Pressure BioSciences' earnings last quarter?: Pressure BioSciences, Inc. (OTCMKTS:PBIO) posted its quarterly earnings results on Tuesday, November, 17th. The company reported ($1.02) earnings per share for the quarter, topping the consensus estimate of ($2.20) by $1.18. The company had revenue of $0.53 million for the quarter.
Read the conference call transcript.
What other stocks do shareholders of Pressure BioSciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Pressure BioSciences investors own include Advanced Micro Devices (AMD), Allena Pharmaceuticals (ALNA), Ampio Pharmaceuticals (AMPE), Actinium Pharmaceuticals (ATNM), Anavex Life Sciences (AVXL), Aware (AWRE), Curaleaf (CURLF) and Walt Disney (DIS).

What is Pressure BioSciences' stock symbol?: Pressure BioSciences trades on the OTCMKTS under the ticker symbol "PBIO."
How do I buy shares of Pressure BioSciences?: Shares of PBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Pressure BioSciences' stock price today?: One share of PBIO stock can currently be purchased for approximately $1.35.
How much money does Pressure BioSciences make?: Pressure BioSciences (OTCMKTS:PBIO) has a market capitalization of $13.34 million and generates $2 million in revenue each year. The company earns $-20,150,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis.
How can I contact Pressure BioSciences?: Pressure BioSciences' mailing address is 14 NORFOLK AVENUE, SOUTH EASTON MA, 02375. The official website for the company is www.pressurebiosciences.com. The company can be reached via phone at 508-230-1828, via email at ir@pressurebiosciences.com, or via fax at 508-230-1829.

This page (OTCMKTS:PBIO) was last updated on 9/26/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial